Good evening :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Oxygenta Pharmaceutical Ltd

OXYGENTAPH

Oxygenta Pharmaceutical Ltd

OXYGENTAPH
0
SmallcapWith a market cap of ₹251 cr, stock is ranked 2,264
High RiskStock is 4.46x as volatile as Nifty
73.103.67% (+2.59)
73.103.67% (+2.59)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
0
SmallcapWith a market cap of ₹251 cr, stock is ranked 2,264
High RiskStock is 4.46x as volatile as Nifty
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

0
SmallcapWith a market cap of ₹251 cr, stock is ranked 2,264
High RiskStock is 4.46x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
25,140.06-12.49—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
7.080.1920.76%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

0

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 13.8%, vs industry avg of -7.98%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.37% to 1.22%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue12.438.7714.2320.8217.7454.3161.8831.1339.7447.38
Raw Materialssubtract8.315.969.5117.7514.9943.0242.6728.6435.0654.42
Power & Fuel Costsubtract1.211.081.120.891.002.793.044.164.15
Employee Costsubtract3.072.862.902.712.504.080.585.745.87
Selling & Administrative Expensessubtract1.371.701.001.431.171.791.881.752.48
Operating & Other expensessubtract2.631.402.34-0.231.92-3.5011.69-1.331.80
Depreciation/Amortizationsubtract0.820.900.941.021.001.201.592.052.662.64
Interest & Other Itemssubtract0.510.600.900.751.091.780.921.491.592.05
Taxes & Other Itemssubtract0.000.090.05-0.24-0.150.210.120.20-10.39-11.74
EPS-5.38-5.71-4.44-3.20-5.672.88-0.50-8.15-1.460.00
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
-0

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Oxygenta Pharmaceutical Ltd-72.24-12.49—
Vashu Bhagnani Industries Ltd97.8110.08—
Worth Investment & Trading Co Ltd312.0016.79—
Aayush Wellness Ltd752.5088.71—

Price Comparison

Compare OXYGENTAPH with any stock or ETF
Compare OXYGENTAPH with any stock or ETF
OXYGENTAPH
Loading...

Shareholdings

Promoter Holdings Trend

Increased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has increased by 23.56%

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding53.28%0.03%0.00%0.00%46.69%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

OXYGENTAPH has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Earnings
Oxygenta Pharmaceutical reports standalone net loss of Rs 2.85 crore in the September 2024 quarter

Net Loss of Oxygenta Pharmaceutical reported to Rs 2.85 crore in the quarter ended September 2024 as against net loss of Rs 3.16 crore during the previous quarter ended September 2023. Sales rose 7.11% to Rs 14.01 crore in the quarter ended September 2024 as against Rs 13.08 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales14.0113.08 7 OPM %-15.49-15.14 - PBDT-2.11-2.32 9 PBT-2.77-3.15 12 NP-2.85-3.16 10 Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Oxygenta Pharmaceutical announces board meeting date

Oxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Oxygenta Pharmaceutical schedules AGM

Oxygenta Pharmaceutical announced that the 31th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Oxygenta Pharmaceutical reports standalone net loss of Rs 1.36 crore in the June 2024 quarter

Net Loss of Oxygenta Pharmaceutical reported to Rs 1.36 crore in the quarter ended June 2024 as against net loss of Rs 4.56 crore during the previous quarter ended June 2023. Sales rose 83.97% to Rs 12.62 crore in the quarter ended June 2024 as against Rs 6.86 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales12.626.86 84 OPM %-14.03-53.06 - PBDT-2.16-3.93 45 PBT-2.81-4.43 37 NP-1.36-4.56 70 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Oxygenta Pharmaceutical to discuss results

Oxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live